Literature DB >> 23393323

Characterization of structure and direct antigen presentation by dendritic/tumor-fused cells as cancer vaccines.

Shigeo Koido1, Jianlin Gong.   

Abstract

BACKGROUND: Previous work has shown that fusion of dendritic cells (DCs) and tumor cells induces potent antitumor immune responses. However, little is known on whether fused cells directly present tumor-associated antigens (TAAs) through major histocompatibility complex (MHC) class I and II pathways in the context of co-stimulatory molecules.
MATERIALS AND METHODS: Fusion cells were generated between DCs and MC38 carcinoma cells stably expressing mucin-1 (MUC1) by polyethylene glycol. The characterization of structure and antigen presentation by fused cells was examined by immunoelectron microscopic and flow cytometric analyses.
RESULTS: The cytoplasm from both cellular entities was integrated, while their nuclei were independently preserved. Short-term culture gave fused cells sufficient time to integrate and directly display MUC1 through MHC class I and II pathways in the context of co-stimulatory molecules.
CONCLUSION: DC-derived molecules and TAAs are presumably synthesized at separate sites of fused cells, to converge and complex with each other.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23393323

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Collagen I enhances the efficiency and anti-tumor activity of dendritic-tumor fusion cells.

Authors:  Jian He; Rong Zheng; Zhenghua Zhang; Jie Tan; Chaofan Zhou; Guoqing Zhang; Xinglu Jiang; Qianyi Sun; Sufang Zhou; Duo Zheng; Yong Huang; Lige Wu; Zongqiang Lai; Jieping Li; Nuo Yang; Xiaoling Lu; Yongxiang Zhao
Journal:  Oncoimmunology       Date:  2017-08-08       Impact factor: 8.110

Review 2.  Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.

Authors:  Mikio Kajihara; Kazuki Takakura; Tomoya Kanai; Zensho Ito; Yoshihiro Matsumoto; Shigetaka Shimodaira; Masato Okamoto; Toshifumi Ohkusa; Shigeo Koido
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

Review 3.  Advances in Immunotherapies for Gliomas.

Authors:  Michael Zhang; John Choi; Michael Lim
Journal:  Curr Neurol Neurosci Rep       Date:  2022-02-02       Impact factor: 6.030

4.  Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells.

Authors:  Matjaz Humar; Marc Azemar; Martina Maurer; Bernd Groner
Journal:  Front Oncol       Date:  2014-10-06       Impact factor: 6.244

Review 5.  Dendritic-Tumor Fusion Cell-Based Cancer Vaccines.

Authors:  Shigeo Koido
Journal:  Int J Mol Sci       Date:  2016-05-26       Impact factor: 5.923

6.  Fusions between dendritic cells and whole tumor cells as anticancer vaccines.

Authors:  Shigeo Koido; Sadamu Homma; Masato Okamoto; Yoshihisa Namiki; Kazuki Takakura; Kan Uchiyama; Mikio Kajihara; Seiji Arihiro; Hiroo Imazu; Hiroshi Arakawa; Shin Kan; Hideo Komita; Masaki Ito; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Oncoimmunology       Date:  2013-05-01       Impact factor: 8.110

7.  Augmentation of antitumor immunity by fusions of ethanol-treated tumor cells and dendritic cells stimulated via dual TLRs through TGF-β1 blockade and IL-12p70 production.

Authors:  Shigeo Koido; Sadamu Homma; Masato Okamoto; Yoshihisa Namiki; Kazuki Takakura; Akitaka Takahara; Shunichi Odahara; Shintaro Tsukinaga; Toyokazu Yukawa; Jimi Mitobe; Hiroshi Matsudaira; Keisuke Nagatsuma; Mikio Kajihara; Kan Uchiyama; Seiji Arihiro; Hiroo Imazu; Hiroshi Arakawa; Shin Kan; Kazumi Hayashi; Hideo Komita; Yuko Kamata; Masaki Ito; Eiichi Hara; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

8.  Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes.

Authors:  Shigeo Koido; Sadamu Homma; Masato Okamoto; Yoshihisa Namiki; Kazuki Takakura; Akitaka Takahara; Shunichi Odahara; Shintaro Tsukinaga; Toyokazu Yukawa; Jimi Mitobe; Hiroshi Matsudaira; Keisuke Nagatsuma; Kan Uchiyama; Mikio Kajihara; Seiji Arihiro; Hiroo Imazu; Hiroshi Arakawa; Shin Kan; Hideo Komita; Masaki Ito; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

Review 9.  Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions.

Authors:  Shigeo Koido; Sadamu Homma; Masato Okamoto; Yoshihisa Namiki; Kazuki Takakura; Kan Uchiyama; Mikio Kajihara; Seiji Arihiro; Hiroo Imazu; Hiroshi Arakawa; Shin Kan; Hideo Komita; Yuko Kamata; Masaki Ito; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Oncoimmunology       Date:  2013-09-12       Impact factor: 8.110

Review 10.  Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting.

Authors:  Alexey V Baldin; Lyudmila V Savvateeva; Alexandr V Bazhin; Andrey A Zamyatnin
Journal:  Cancers (Basel)       Date:  2020-03-05       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.